Researchers Say Estrogen Can Kill Breast Cancer Cells Once Fueled by the Hormone
PHILADELPHIA -- Fox Chase Cancer Center researchers say some breast cancer cells once fueled by estrogen can be killed by the same hormone. This raises the possibility that estrogen therapy after estrogen deprivation may overcome the cells' eventual resistance to hormone therapy. The finding by V. Craig Jordan, PhD, D Sc, and his colleagues at Fox Chase is published in the December 7 issue of the Journal of the National Cancer Institute.
Many breast cancer cells (called estrogen receptor-positive breast cancers) require estrogen for survival. Women with these types of breast cancers are treated with drugs that that block estrogen, such as tamoxifen, fulvestrant, or aromatase inhibitors, causing the cells to die in a process called apoptosis. However, over time, these cancer cells learn to adapt and become resistant to this therapy.
"Tamoxifen and other estrogen inhibition drugs have been remarkably successful in the treatment of hormone-responsive breast cancers," said Jordan, vice president and scientific director for the medical science division at Fox Chase. "However, cancer cells are smart and they figure out how to survive these treatments. We believe we've become savvy to their art. Our laboratory study demonstrates that these same breast cancer cells die when we re-introduce them to estrogen." Jordan was the leader in the development of the use of tamoxifen to treat breast cancer. He holds the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research at Fox Chase.
The mechanism by which estrogen promotes apoptosis is not well understood. To understand this process, Jordan and his colleagues developed a line of breast cancer cells, called MCF-7:5C. These cells already are resistant to estrogen withdrawal. When the researchers treated MCF-7:5C cells with very small concentrations of estradiol they underwent apoptosis. The researchers also tested these cells in mice to see how this process might influence existing tumors. Again, the exposure to estradiol caused the cancer cells to die.
"These laboratory data have important clinical implications, particularly for the use of aromatase inhibitors as long-term therapy," write the authors, "and they suggest that, if and when resistance to aromatase inhibition occurs, a strategy of treatment with estrogen ... may be sufficient to kill the cancer and control disease progression."
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Diana Quattrone at 215-728-7784.